GYY 4137 Morpholine salt

Product NameGYY 4137 Morpholine salt
CAS106740-09-4
MFC15H25N2O3PS2
MW376.474361
EINECS
MOL File106740-09-4.mol

Chemical Properties

Melting point	164-166℃
storage temp.	2-8°C
solubility	DMF: 20 mg/ml; DMSO: 15 mg/ml; PBS (pH 7.2): 3 mg/ml
form	White solid.
color	White
InChI	InChI=1S/C11H16NO2PS2.C4H9NO/c1-13-10-2-4-11(5-3-10)15(16,17)12-6-8-14-9-7-12;1-3-6-4-2-5-1/h2-5H,6-9H2,1H3,(H,16,17);5H,1-4H2
InChIKey	YZMHNNLDUWRZFW-UHFFFAOYSA-N
SMILES	C1C(OC)=CC=C(P([S-])(N2CCOCC2)=S)C=1.C1C[N+]([H])([H])CCO1

Safety Information

WGK Germany	WGK 3
Storage Class	11 - Combustible Solids

Usage And Synthesis

Description

Hydrogen sulfide (H₂S) is a gaseous mediator which, like nitric oxide (NO), has numerous profound actions in mammalian physiology. GYY 4137 is a water-soluble, slow-releasing hydrogen sulfide (H₂S) donor. When given intravenously, it demonstrates vasodilator and anti-hypertensive activity in rats, in either the acute (L-NAME-induced) or chronic (spontaneously hypertensive) hypertension models. Intravenous GYY 4137 also protects against endotoxic shock in rats, inhibiting tumor necrosis factor-α, interleukin (IL)-1β, and IL-6 production and reducing NF-κB activation, iNOS and cyclooxygenase-2 expression, and NO and prostaglandin E₂ generation.

Uses

GYY 4137 is a slow releasing hydrogen sulfide donor.

Uses

Hydrogen sulfide (H2S) is a gaseous mediator which, like nitric oxide (NO), has numerous profound actions in mammalian physiology. GYY 4137 is a water-soluble, slow-releasing hydrogen sulfide (H2S) donor. When given intravenously, it demonstrates vasodilator and anti-hypertensive activity in rats, in either the acute (L-NAME-induced) or chronic (spontaneously hypertensive) hypertension models. Intravenous GYY 4137 also protects against endotoxic shock in rats, inhibiting tumor necrosis factor-α, interleukin (IL)-1β, and IL-6 production and reducing NF-κB activation, iNOS and cyclooxygenase-2 expression, and NO and prostaglandin E2 generation.[Cayman Chemical]

in vivo

GYY4137 (100-300 mg/kg; i.p.; daily for 14 days) significantly reduces the tumor volume in both animal models, in a dose-dependent manner^[2].
In the complete Freund's adjuvant (CFA)-treated mouse, GYY4137 (50 mg/kg, i.p.) injected 1 hr prior to CFA increased knee joint swelling while an anti-inflammatory effect, as demonstrated by reduced synovial fluid myeloperoxidase (MPO) and N-acetyl-β-D-glucosaminidase (NAG) activity and decreased TNF-α, IL-1β, IL-6 and IL-8 concentration, was apparent when GYY4137 was injected 6 hrs after CFA^[3].
GYY4137 significantly inhibited tumor growth in the subcutaneous HepG2 xenograft model by inhibiting STAT3 activation and its target gene expression^[4].
GYY4137 prevents nitrative stress and α-synuclein nitration in an MPTP mouse model of parkinson’s disease^[5].

Animal Model:	Female, severe combined immunodeficiency (SCID) mice (bearing HL-60 or MV4-11 cells)^[2]
Dosage:	100, 200 and 300 mg/kg
Administration:	I.p.; daily for 14 days
Result:	Reduced tumor volume by 52.5% and 55.3% in HL-60 and MV4–11 injected animals.

IC 50

Stat-3

storage

+4°C

References

[1] LING LI. Characterization of a novel, water-soluble hydrogen sulfide-releasing molecule (GYY4137): new insights into the biology of hydrogen sulfide.[J]. Circulation, 2008, 117 18: 2351-2360. DOI: 10.1161/circulationaha.107.753467
[2] LING LI . GYY4137, a novel hydrogen sulfide-releasing molecule, protects against endotoxic shock in the rat[J]. Free Radical Biology and Medicine, 2009, 47 1: Pages 103-113. DOI: 10.1016/j.freeradbiomed.2009.04.014
[3] PETER J ELLIOTT Wolf H B Thomas Matthias Zollner. Proteasome inhibition: a new anti-inflammatory strategy.[J]. Journal of Molecular Medicine-Jmm, 2003, 81 4: 235-245. DOI: 10.1007/s00109-003-0422-2

GYY 4137 Morpholine salt Supplier

GYY 4137 Morpholine salt manufacturers

Related Product Information

Send Inquriy